Vertex Pharmaceuticals Inc / Ma
—- Market cap
- $130.42B
- Debt
- —
- Cash
- −$5.08B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $130.42B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: VRTX stock price vs BRKR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BRKR's multiple
Needs BRKR P/E.
Implied fair value · at VRTX's multiple
Needs Annual EPS is negative.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BRUKER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
THERMO FISHER SCIENTIFIC INC.
VRTX vs TMO
DANAHER CORP /DE/
VRTX vs DHR
AGILENT TECHNOLOGIES, INC.
VRTX vs A
WATERS CORP /DE/
VRTX vs WAT
BIO-RAD LABORATORIES, INC.
VRTX vs BIO
BIO-TECHNE Corp
VRTX vs TECH
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX can sustain its premium margins and high ROIC long enough to close the gap to the upper end of its valuation band, then hold or accumulate only on meaningful pullbacks; otherwise, the current price looks difficult to justify versus the DCF and BRKR-implied ranges because the stock already embeds a large premium.
The valuation gap is extreme: VRTX's current price of $490.43 versus an implied price of $110.96 implies -77.4% downside on the stated P/S basis. That said, VRTX also trades well above the DCF range and near the upper end of the historical band, so the market is already pricing in a premium for its superior quality and profitability.
Supporting Metrics